Glimepiride Strandhaven

Glimepiride Strandhaven is an oral tablet containing the active ingredient glimepiride, a sulfonylurea antidiabetic medication approved for prescription use in the European Union. It belongs to the therapeutic class of antidiabetic agents and works by stimulating insulin release from pancreatic beta cells to help control blood glucose levels in adults with type 2 diabetes mellitus.

Glimepiride Strandhaven is prescribed to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, often as part of a comprehensive diabetes management plan that includes diet and exercise.

- Used as monotherapy when metformin alone does not achieve target glucose levels. - Added to metformin therapy for synergistic glucose‑lowering effect. - May be combined with other oral antidiabetic agents under physician guidance. - Helps reduce fasting and post‑prandial blood glucose concentrations. - Utilized in patients who can tolerate sulfonylureas without severe hypoglycemia.

Glimepiride Strandhaven may cause a range of side effects, most of which are mild and transient, while some require immediate medical attention.

Common: - Mild hypoglycemia, especially if meals are missed. - Headache or dizziness. - Nausea or abdominal discomfort. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia leading to confusion or loss of consciousness. - Allergic reactions such as rash, itching, or swelling. - Hematologic abnormalities like leukopenia or thrombocytopenia.

Before starting Glimepiride Strandhaven, certain precautions should be considered to ensure safe and effective use.

- Assess renal and hepatic function, as impairment may increase drug exposure. - Monitor blood glucose regularly to avoid hypoglycemia. - Use cautiously in elderly patients who may be more sensitive to glucose‑lowering effects. - Discontinue or adjust dose before surgical procedures or during acute illness. - Avoid use during pregnancy and lactation unless clearly indicated by a healthcare professional. - Review any history of cardiovascular disease, as sulfonylureas may affect cardiac outcomes.

Glimepiride Strandhaven can interact with several medications, altering its efficacy or safety profile.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma levels. - Certain non‑steroidal anti‑inflammatory drugs (NSAIDs) that may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may raise blood glucose. - Oral contraceptives, as they may slightly reduce glimepiride effectiveness. - Antifungal agents like ketoconazole, requiring possible dose adjustment.